BPC-157 (Oral) vs TB-500
A side-by-side research comparison of BPC-157 (Oral) and TB-500 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | TB-500 |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Thymosin Beta-4 (Synthetic) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | Upregulates actin production to promote cell migration and proliferation, enhances angiogenesis, and reduces pro-inflammatory cytokines. |
| Molecular weight | 1419.53 Da | 4921 Da |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | ~6 hours |
| Bioavailability | ~40-60% oral (arginate salt form) | ~95% via subcutaneous injection |
| Typical dose | 500 mcg - 1 mg | 2-5 mg per dose |
| Frequency | 1-2x daily | Loading: 2x/week · Maintenance: 1x/week |
| Route | Oral capsule (arginate salt) | Subcutaneous injection |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
TB-500 reported benefits
- Enhanced wound healing
- Reduced inflammation
- Improved flexibility
- Cardiac tissue repair
- Hair regrowth support
Related comparisons
Research and educational reference only. Not medical advice.